Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis

Phase 2 Recruiting 8 enrolled Paul Szabolcs

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether a regimen of high-dose immunoablative therapy will demonstrate safety that is consistent or improved with other published regimens in SSc patients, while maintaining a treatment effect.

Timeline

Start: 2018-07-31
Primary completion: 2026-08-01
Completion: 2026-08-01

Publications

Torok KS, Horvei P, Li J, Rosser F, Alexander JL, Rose-Felker K, Sood V, Olson A, Hogue N, Vandergrift V, Stanczak H, Miglioretti M, Farver L, Koster W, Mcguire D, Havrilla H, McIntyre S, Domsic RT, Lafyatis RA, Szabolcs P. Autologous stem cell transplantation (ASCT) for Refractory juvenile-onset systemic sclerosis (JSSc). Ann Rheum Dis. 2026 Jun 17:S0003-4967(26)00299-2. doi: 10.1016/j.ard.2026.05.022. Online ahead of print.

Drugs

Evaluation	Drug	Modality	Dose	Route
Background	2-MERCAPTOETHANESULFONIC ACID	Small molecule	—	—
Background	ANTILYMPHOCYTE IMMUNOGLOBULIN (HORSE)	Protein / enzyme biologic	—	—
Background	Alemtuzumab	Monoclonal antibody	—	—
Background	Cyclophosphamide	Other / unclassified	—	—
Background	Immune Globulin Intravenous (Human)	Protein / enzyme biologic	—	—
Background	Rituximab	Monoclonal antibody	—	—
Background	Thiotepa	Other / unclassified	—	—
Background	sargramostim	Protein / enzyme biologic	—	—

Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis

Summary

Timeline

Publications

Drugs

Indications